Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04255680 · ClinicalTrials.gov registry record
A Study to Assess Variation in Potential Biomarkers in Friedreich Ataxia
A clinical trial, sponsored by Larimar Therapeutics.
- Completed
- Registry status
- 20
- Enrollment target
NCT04255680 is a clinical trial that has completed, run by Larimar Therapeutics. The registered enrollment target is 20 participants.
The verdict
NCT04255680 has completed, sponsored by Larimar Therapeutics.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
Study Summary
To test the variability of specific ribonucleic acid (RNA) and proteins as well as frataxin levels in samples of blood and buccal cells taken directly from patients with Friedreich's ataxia (FRDA) in order to confirm potential new biomarkers of disease in patients with FRDA.
Interventions
- DIAGNOSTIC_TEST Buccal Swabs and Blood Draws
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-01-14 |
| Est. Completion | 2020-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04255680
The ClinicalTrials.gov registry entry for NCT04255680 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Larimar Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Buccal Swabs and Blood Draws is the first listed.
NCT04255680 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04255680 about?
NCT04255680 is a clinical study titled "A Study to Assess Variation in Potential Biomarkers in Friedreich Ataxia". To test the variability of specific ribonucleic acid (RNA) and proteins as well as frataxin levels in samples of blood and buccal cells taken directly from patients with Friedreich's ataxia (FRDA) in order to confirm potential new biomarkers of disease in patients with FRDA.
What is the current status of trial NCT04255680?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2020-01-14. Estimated completion is 2020-06-30.
What interventions are being tested in trial NCT04255680?
The interventions under investigation include: Buccal Swabs and Blood Draws (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04255680?
This trial is sponsored by Larimar Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.